Business Wire

CO-TECHSTARS

6.1.2022 14:02:13 CET | Business Wire | Press release

Share
Techstars Announces Two New Executive Team Leaders: Rupa Athreya Appointed Chief Accelerator Investments Officer & Marie Moussavou Appointed Chief Portfolio Services Officer

Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, has created two new leadership roles as the company continues to scale to serve more founders around the world. With $850 million in assets under management, 47 accelerator programs in 17 countries, and a global alumni base of more than 2,700 companies, both roles will provide strategic and operational support to thousands of entrepreneurs. Athreya and Moussavou will report directly to the company’s CEO, Maelle Gavet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005289/en/

“Techstars has an unprecedented ability to impact entrepreneurs through our unique pre-seed investment model that identifies exceptional entrepreneurs worldwide and supports them operationally and financially as they build their businesses,” stated Gavet. “We count on globally experienced executives with the ability to think big-picture, enabling the organization to operate at scale which is why both Marie and Rupa are such wonderful additions to our global management team.”

As the company’s first Chief Accelerator Investments Officer, Rupa Athreya will lead a worldwide team of more than 75 investment professionals who represent Techstars in 37 cities around the world. Techstars operates under the principle that the best founders can come from anywhere, running programs locally in the cities where the entrepreneurs operate or seek to grow. Techstars maintains a small class size ranging from 10 to 12 portfolio companies and runs multiple programs in cities with larger entrepreneur ecosystems. Techstars’ Accelerator Investment Team invested approximately $94 million last year and will continue to grow its portfolio as investors around the world seek to invest in viable early-stage companies. Overseeing this decentralized approach requires a seasoned executive with a strategic mindset, strong operational skills and global experience.

Having worked at global firms such as OppenheimerFunds, JPMorgan Chase, Bloomberg and McKinsey, Athreya has most recently been an independent consultant advising startups and new businesses as well as global financial institutions on strategy, innovation, and go-to-market execution. She has close to 20 years of expertise in building and launching new businesses and products, having led product development at OppenheimerFunds, founded a robo-advisor at Bloomberg and launched the Chase Private Client business at JPMorgan Chase. She has a Ph.D. in Economics from Yale University, a B.A. in Philosophy, Politics and Economics from Oxford University and a B.A. in Economics from the University of Delhi. She will continue to be based out of New York, NY.

As Techstars’ first Chief Portfolio Services Officer, Marie Moussavou will be responsible for advancing growth, providing infrastructure support and investment opportunities for Techstars’ more than 6,500 alumni founders as they lead their companies through later stages. Portfolio Services provides capital and funding, business development and talent connections, mentorship, and knowledge exchange for Techstars’ network of founders, investors, mentors and innovation partners. With this ever-growing network, the Portfolio Services team under Moussavou’s leadership will maintain deep, personal relationships with founders while leveraging robust data management skills to offer founders customized and scalable support.

Moussavou has a proven track record of scaling high growth, customer-focused organizations through innovation and operational excellence. Most recently she worked at Amazon for 15 years in various senior roles, including Technical Advisor to the SVP for International, Director of Alexa Europe, and Director of Operations for Amazon Transportation Services Europe. Marie has an MBA from the London Business School and lives in London, U.K., where she will continue to be based.

About Techstars

The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,800 companies with a combined market cap of more than $195B. www.techstars.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release

Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release

ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document

SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release

Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as

Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release

Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye